论文部分内容阅读
目的比较吉西他滨联合顺铂(GP)方案治疗老年和中年晚期非小细胞肺癌(NSCLC)患者的客观有效率(RR)、中位疾病进展时间(mTTP)、毒副反应。方法回顾研究我院2007至2009年收治的70例接受GP方案化疗的晚期NSCLC患者,根据年龄分为两组。结果:70例患者均有可评价病灶。老年组和中年组有效率分别为38.9%和41.2%;两组mTTP时间为5.2和6.0个月;老年组中Ⅲ、Ⅳ度粒细胞及血小板减少、恶心呕吐、乏力的发生率分别为25.0%、22.2%、25.0%、11.1%,而中年组为20.6%、17.6%、5.9%和2.9%。结论对于老年晚期非小细胞肺癌患者,吉西他滨联合顺铂是安全、有效的联合化疗方案。
Objective To compare the objective response rate (RR), median time to progression (mTTP), and toxicity of gemcitabine plus cisplatin (GP) regimen in elderly and middle-aged patients with advanced non-small cell lung cancer (NSCLC) Methods A retrospective study of 70 patients with advanced NSCLC treated with GP regimen from 2007 to 2009 in our hospital was divided into two groups according to their age. Results: All 70 patients had evaluable lesions. The effective rates of the elderly group and the middle-aged group were 38.9% and 41.2% respectively; the mTTP duration was 5.2 and 6.0 months in both groups; the incidence of grade Ⅲ and Ⅳ granulocyte and thrombocytopenia, nausea and vomiting and fatigue in the elderly group were 25.0 %, 22.2%, 25.0%, 11.1%, while the middle-aged group was 20.6%, 17.6%, 5.9% and 2.9%, respectively. Conclusions Gemcitabine plus cisplatin is a safe and effective combination chemotherapy in elderly patients with advanced non-small cell lung cancer.